92.66
2.04 (2.25%)
| Penutupan Terdahulu | 90.62 |
| Buka | 91.00 |
| Jumlah Dagangan | 568,142 |
| Purata Dagangan (3B) | 1,873,828 |
| Modal Pasaran | 18,440,681,472 |
| Harga / Pendapatan (P/E TTM) | 14.46 |
| Harga / Pendapatan (P/E Ke hadapan) | 11.74 |
| Harga / Jualan (P/S) | 3.54 |
| Harga / Buku (P/B) | 3.50 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 28 Apr 2026 |
| Margin Keuntungan | 0.48% |
| Margin Operasi (TTM) | 20.65% |
| EPS Cair (TTM) | 0.200 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 19.50% |
| Pertumbuhan Pendapatan Suku Tahunan (YOY) | -6.70% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 1.18% |
| Nisbah Semasa (MRQ) | 2.04 |
| Aliran Tunai Operasi (OCF TTM) | 382.59 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | 618.05 M |
| Pulangan Atas Aset (ROA TTM) | 2.04% |
| Pulangan Atas Ekuiti (ROE TTM) | 0.47% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Incyte Corporation | Menaik | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 1.5 |
| Aktiviti Orang Dalam | -1.5 |
| Volatiliti Harga | 1.0 |
| Purata Bergerak Teknikal | 1.5 |
| Osilator Teknikal | -0.5 |
| Purata | 0.40 |
|
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Mid Core |
| % Dimiliki oleh Orang Dalam | 2.01% |
| % Dimiliki oleh Institusi | 100.65% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Los Angeles Capital Management Llc | 31 Dec 2025 | 2,288,874 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 135.00 (HC Wainwright & Co., 45.69%) | Beli |
| Median | 110.00 (18.71%) | |
| Rendah | 92.00 (RBC Capital, -0.71%) | Pegang |
| Purata | 111.89 (20.75%) | |
| Jumlah | 5 Beli, 4 Pegang | |
| Harga Purata @ Panggilan | 101.38 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| HC Wainwright & Co. | 09 Mar 2026 | 135.00 (45.69%) | Beli | 97.10 |
| 11 Feb 2026 | 135.00 (45.69%) | Beli | 98.84 | |
| Evercore ISI Group | 05 Mar 2026 | 110.00 (18.71%) | Pegang | 97.33 |
| Barclays | 18 Feb 2026 | 117.00 (26.27%) | Beli | 102.99 |
| 04 Feb 2026 | 116.00 (25.19%) | Beli | 102.60 | |
| RBC Capital | 11 Feb 2026 | 92.00 (-0.71%) | Pegang | 98.84 |
| Stifel | 11 Feb 2026 | 120.00 (29.51%) | Beli | 98.84 |
| Wells Fargo | 11 Feb 2026 | 101.00 (9.00%) | Pegang | 98.84 |
| 20 Jan 2026 | 107.00 (15.48%) | Pegang | 102.62 | |
| Piper Sandler | 06 Feb 2026 | 110.00 (18.71%) | Beli | 108.39 |
| TD Cowen | 13 Jan 2026 | 128.00 (38.14%) | Beli | 103.43 |
| Morgan Stanley | 06 Jan 2026 | 94.00 (1.45%) | Pegang | 106.66 |
| Papar semua | ||||
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| CAGNONI PABLO J | - | 94.22 | -18,667 | -1,758,805 |
| Jumlah Keseluruhan Kuantiti Bersih | -18,667 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | -1,758,805 | |||
| Purata Pembelian Keseluruhan ($) | - | |||
| Purata Jualan Keseluruhan ($) | 94.22 | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| CAGNONI PABLO J | Pegawai | 17 Mar 2026 | Jual (-) | 18,667 | 94.22 | 1,758,805 |
| CAGNONI PABLO J | Pegawai | 17 Mar 2026 | Pelaksanaan pilihan | 18,667 | - | - |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |